RNAi screen analysis of viral host genes
Reference | Disease | Gene | SNP ID | SNP | p-value | Virus |
---|---|---|---|---|---|---|
Reference | Disease | Gene | SNP ID | SNP | p-value | Virus |
23704328 | Primary tooth development (number of teeth) | ADK | 132 | rs7924176 | 8.00E-16 | HCV |
21829377 | Phospholipid levels (plasma) | AGPAT3 | 56894 | rs7435 | 2.00E-07 | HCV |
22484627 | Obesity | ALPK1 | 80216 | rs4833407 | 1.00E-06 | HCV |
21799462 | Epirubicin-induced leukopenia | ALPK1 | 80216 | rs6838440 | 3.00E-06 | HCV |
23593239 | Self-employment | ARHGAP22 | 58504 | rs10776614 | 7.00E-06 | HCV |
21310492 | Diabetic retinopathy | ARHGAP22 | 58504 | rs4838605 | 2.00E-09 | HCV |
20585324 | Conduct disorder (case status) | ARHGAP22 | 58504 | rs10776612 | 2.00E-06 | HCV |
23251661 | Obesity-related traits | ARHGEF10L | 55160 | rs6693036 | 3.00E-06 | HCV |
24204828 | Fasting insulin (interaction) | ARHGEF7 | 8874 | rs12853515 | 4.00E-06 | HCV |
19414484 | Bilirubin levels | ARHGEF7 | 8874 | rs4773330 | 8.00E-06 | HCV |
21983787 | Melanoma | ATM | 472 | rs1801516 | 3.00E-09 | HCV |
22359512 | Sphingolipid levels | ATP10D | 57205 | rs13106975 | 2.00E-19 | HCV |
19798445 | Sphingolipid levels | ATP10D | 57205 | rs10938494 | 8.00E-19 | HCV |
23583980 | Interstitial lung disease | ATP11A | 23250 | rs1278769 | 7.00E-09 | HCV |
23563607 | Height | BCKDHB | 594 | rs2322633 | 3.00E-09 | HCV |
23263486 | Urate levels | BMPR2 | 659 | rs12468226 | 3.00E-06 | HCV |
22437554 | Response to Vitamin E supplementation | BRAF | 673 | rs17623382 | 4.00E-06 | HCV |
22139419 | Mean platelet volume | BRF1 | 2972 | rs3000073 | 3.00E-11 | HCV |
23563607 | Obesity | CADM2 | 253559 | rs13078807 | 3.00E-11 | HCV |
22589738 | Visceral fat | CADM2 | 253559 | rs13323436 | 3.00E-06 | HCV |
21546767 | Dialysis-related mortality | CALM2 | 805 | rs815815 | 7.00E-07 | HCV |
19011631 | Colorectal cancer | CDH1 | 999 | rs9929218 | 1.00E-08 | HCV |
23958962 | Cocaine dependence | CDK1 | 983 | rs2456778 | 5.00E-06 | HCV |
23273568 | Systemic lupus erythematosus | CDKN1B | 1027 | rs34330 | 5.00E-12 | HCV |
21833088 | Multiple sclerosis | CHST12 | 55501 | rs6952809 | 4.00E-06 | HCV |
22726844 | QT interval | CNOT1 | 23019 | rs37060 | 1.00E-07 | HCV |
19305408 | QT interval | CNOT1 | 23019 | rs37062 | 3.00E-25 | HCV |
22959728 | Amyotrophic lateral sclerosis (age of onset) | CNOT2 | 4848 | rs2904524 | 5.00E-06 | HCV |
23263863 | Platelet counts | COPZ1 | 22818 | rs4326844 | 5.00E-08 | HCV |
19176441 | Response to treatment for acute lymphoblastic leukemia | DGKB | 1607 | rs6971925 | 3.00E-06 | HCV |
20881960 | Height | DOCK3 | 1795 | rs13088462 | 4.00E-10 | HCV |
21531791 | Glioma | EGFR | 1956 | rs11979158 | 7.00E-08 | HCV |
22969067 | Corneal curvature | EIF2AK4 | 440275 | rs2250402 | 6.00E-06 | HCV |
24024966 | Periodontitis (Mean PAL) | ERC2 | 26059 | rs1875110 | 4.00E-06 | HCV |
21057379 | Bipolar disorder and schizophrenia | ERC2 | 26059 | rs1795648 | 6.00E-06 | HCV |
21160409 | HIV-1 susceptibility | FAM174B | 400451 | rs285757 | 7.00E-06 | HCV |
22699663 | Periodontal microbiota | FBXO38 | 81545 | rs10043775 | 2.00E-06 | HCV |
20881960 | Height | FER | 2241 | rs13177718 | 3.00E-08 | HCV |
20152958 | Fasting plasma glucose | FOXA2 | 3170 | rs1209523 | 2.00E-11 | HCV |
18985386 | Parkinson's disease (familial) | GAK | 2580 | rs1564282 | 7.00E-07 | HCV |
20711177 | Parkinson's disease | GAK | 2580 | rs11248051 | 3.00E-09 | HCV |
23575436 | Glycemic traits | GCK | 2645 | rs1799884 | 5.00E-18 | HCV |
19096518 | Glycated hemoglobin levels | GCK | 2645 | rs730497 | 6.00E-12 | HCV |
20881960 | Height | GIT1 | 28964 | rs3110496 | 7.00E-09 | HCV |
20125193 | Cognitive performance | IDS | 3423 | rs530501 | 4.00E-06 | HCV |
22952603 | Response to amphetamines | IGSF11 | 152404 | rs2160050 | 9.00E-06 | HCV |
23966867 | Waist circumference | LHX2 | 9355 | rs2075064 | 2.00E-08 | HCV |
21909110 | Blood pressure | MAP4 | 4134 | rs319690 | 3.00E-08 | HCV |
21833088 | Multiple sclerosis | MAPK1 | 5594 | rs2283792 | 5.00E-09 | HCV |
22504420 | Bone mineral density | MARK3 | 4140 | rs11623869 | 5.00E-16 | HCV |
24097068 | Triglycerides | MET | 4233 | rs38855 | 2.00E-08 | HCV |
19010793 | Multiple sclerosis (severity) | MET | 4233 | rs10243024 | 6.00E-06 | HCV |
22399527 | Metabolic syndrome | MLXIPL | 51085 | rs13226650 | 2.00E-11 | HCV |
22286219 | Lipid metabolism phenotypes | MLXIPL | 51085 | rs13247874 | 8.00E-14 | HCV |
22001757 | Liver enzyme levels (gamma-glutamyl transferase) | MLXIPL | 51085 | rs17145750 | 3.00E-09 | HCV |
18193046 | Triglycerides | MLXIPL | 51085 | rs3812316 | 1.00E-10 | HCV |
23534349 | PR interval | MYO3A | 53904 | rs16926523 | 4.00E-06 | HCV |
23251661 | Obesity-related traits | MYO3A | 53904 | rs12764197 | 6.00E-06 | HCV |
23251661 | Obesity-related traits | MYO3A | 53904 | rs2096176 | 5.00E-06 | HCV |
23738518 | Word reading | NOS1AP | 9722 | rs11577628 | 5.00E-06 | HCV |
23251661 | Obesity-related traits | NOS1AP | 9722 | rs76662883 | 9.00E-06 | HCV |
22726844 | QT interval | NOS1AP | 9722 | rs4657175 | 1.00E-09 | HCV |
20062061 | Electrocardiographic traits | NOS1AP | 9722 | rs1415259 | 7.00E-10 | HCV |
20062063 | Electrocardiographic traits | NOS1AP | 9722 | rs10494366 | 5.00E-22 | HCV |
19305408 | QT interval | NOS1AP | 9722 | rs12029454 | 3.00E-45 | HCV |
19305408 | QT interval | NOS1AP | 9722 | rs16857031 | 1.00E-34 | HCV |
19305409 | QT interval | NOS1AP | 9722 | rs4657178 | 7.00E-33 | HCV |
23921680 | Allergic dermatitis (nickel) | PELI1 | 57162 | rs6733160 | 7.00E-06 | HCV |
21221998 | Kawasaki disease | PELI1 | 57162 | rs7604693 | 2.00E-06 | HCV |
23996088 | Acute lymphoblastic leukemia (B-cell precursor) | PIP4K2A | 5305 | rs10828317 | 2.00E-09 | HCV |
23251661 | Obesity-related traits | PIP4K2A | 5305 | rs7094131 | 9.00E-06 | HCV |
23263486 | Urate levels | PRKAG2 | 51422 | rs10480300 | 4.00E-09 | HCV |
21305692 | Bipolar disorder (age of onset and psychomotor symptoms) | PRKAG2 | 51422 | rs7795096 | 2.00E-06 | HCV |
20383146 | Chronic kidney disease | PRKAG2 | 51422 | rs7805747 | 4.00E-12 | HCV |
19862010 | Hematocrit | PRKAG2 | 51422 | rs10224002 | 6.00E-15 | HCV |
21107309 | Reasoning | PRKCZ | 5590 | rs3753242 | 1.00E-06 | HCV |
20881960 | Height | PRKCZ | 5590 | rs425277 | 2.00E-08 | HCV |
20139978 | White blood cell count | PSMD3 | 5709 | rs4065321 | 3.00E-14 | HCV |
24162737 | Alzheimer's disease (late onset) | PTK2B | 2185 | rs28834970 | 7.00E-14 | HCV |
22542470 | Immune response to smallpox vaccine (IL-6) | RAB10 | 10890 | rs13388915 | 8.00E-06 | HCV |
24097068 | Cholesterol, total | RAF1 | 5894 | rs2290159 | 2.00E-09 | HCV |
21348951 | Cardiac hypertrophy | RAF1 | 5894 | rs3729931 | 7.00E-07 | HCV |
20018961 | Leprosy | RIPK2 | 8767 | rs42490 | 1.00E-16 | HCV |
19305408 | QT interval | RNF207 | 388591 | rs846111 | 1.00E-16 | HCV |
22504420 | Bone mineral density | RPS6KA5 | 9252 | rs1286083 | 2.00E-15 | HCV |
23251661 | Obesity-related traits | RPS6KB1 | 6198 | rs1051424 | 3.00E-06 | HCV |
21833088 | Multiple sclerosis | RPS6KB1 | 6198 | rs180515 | 9.00E-08 | HCV |
23612905 | Graves' disease | SLAMF6 | 114836 | rs1265883 | 2.00E-18 | HCV |
22589738 | Subcutaneous adipose tissue | SMAD6 | 4091 | rs11858577 | 9.00E-06 | HCV |
24024966 | Periodontitis (Mean PAL) | SMURF2 | 64750 | rs111854052 | 9.00E-06 | HCV |
22837378 | Airflow obstruction | SPATA13 | 221178 | rs715921 | 8.00E-07 | HCV |
23266558 | Crohn's disease | STAT3 | 6774 | rs9891119 | 2.00E-15 | HCV |
23128233 | Inflammatory bowel disease | STAT3 | 6774 | rs12942547 | 6.00E-22 | HCV |
22190364 | Multiple sclerosis | STAT3 | 6774 | rs2293152 | 4.00E-08 | HCV |
20159113 | Multiple sclerosis | STAT3 | 6774 | rs744166 | 3.00E-10 | HCV |
23251661 | Obesity-related traits | STIM2 | 57620 | rs6822297 | 8.00E-06 | HCV |
21829377 | Phospholipid levels (plasma) | STIM2 | 57620 | rs6844153 | 6.00E-07 | HCV |
22005930 | Alzheimer's disease | STK11 | 6794 | rs3764640 | 8.00E-06 | HCV |
23722424 | Educational attainment | STK24 | 8428 | rs3783006 | 8.00E-08 | HCV |
22159054 | Alzheimer's disease | STK24 | 8428 | rs912330 | 4.00E-06 | HCV |
20834067 | Longevity | STK24 | 8428 | rs9517320 | 1.00E-06 | HCV |
23382691 | IgG glycosylation | SUV420H1 | 51111 | rs4930561 | 1.00E-08 | HCV |
22566498 | Response to angiotensin II receptor blocker therapy | SYNRG | 11276 | rs2074409 | 2.00E-06 | HCV |
23897914 | Bronchopulmonary dysplasia | TNK2 | 10188 | rs2278034 | 5.00E-06 | HCV |
24097068 | Cholesterol, total | TOP1 | 7150 | rs6029526 | 1.00E-16 | HCV |
22423221 | Mean platelet volume | TPM4 | 7171 | rs8109288 | 5.00E-10 | HCV |
20383146 | Chronic kidney disease | WDR37 | 22884 | rs10794720 | 1.00E-08 | HCV |
23551011 | Preeclampsia | WWTR1 | 25937 | rs17787940 | 3.00E-06 | HCV |
22960999 | Esophageal cancer (squamous cell) | XBP1 | 7494 | rs2239815 | 4.00E-15 | HCV |